Nov 12, 2022 by James Halley2 No-Brainer Stocks to Buy Right Now for Less than $20These stocks are still bargain-priced but benefit from long-term trends.
Nov 11, 2022 by James HalleyWhy Shares of TG Therapeutics Climbed 59.9% This WeekThe company got a big bump from the FDA.
Nov 11, 2022 by James HalleyWhy Shares of NeoGenomics Jumped 53.9% This WeekThe cancer screening company showed its turnaround may be working.
Nov 11, 2022 by James HalleyWhy Certara's Shares Rose 37.7% This WeekThe company, which helps other companies in their drug development, reported strong third-quarter numbers.
Nov 10, 2022 by James HalleyWhy Shares of Teladoc Rose 15.77% on ThursdayMarket forces, and the lingering benefit of improved third-quarter numbers, drove the stock up.
Nov 10, 2022 by James HalleyWhy TG Therapeutics' Shares Rose 63.37% on ThursdayThe company had a nugget of good news in its third-quarter report.
Nov 10, 2022 by James HalleyWhy EQRx Shares Dropped 28.62% on ThursdayThe company suspended trials for one of its lead therapies.
Nov 10, 2022 by James Halley3 Top Healthcare Stocks Defying the Bear MarketThese healthcare companies haven't been slowed by macroeconomic conditions.
Nov 9, 2022 by James HalleyWhy Shares of Bioventus Fell 14% on WednesdayThe company's reduced guidance concerned investors.
Nov 9, 2022 by James HalleyWhy Shares of Health Catalyst Popped 23.34% on WednesdayThe company continued its upward trend in revenue growth.
Nov 9, 2022 by James HalleyWhy Shares of Eastman Kodak Slumped 23.64% on WednesdayInvestors saw cause for concern in the company's third-quarter earnings.
Nov 8, 2022 by James HalleyWhy Shares of Gilead Sciences Rose 27.20% in OctoberThe company's growing oncology portfolio is driving increased revenues.
Nov 8, 2022 by James Halley3 No-Brainer Stocks to Buy in a DownturnThese companies thrive when others falter.
Nov 8, 2022 by James HalleyThese 3 Dividend ETFs Are a Retiree's Best FriendThis trio of exchange-traded funds has trounced the S&P 500 this year.
Nov 7, 2022 by James HalleyWhy Shares of Doximity Dropped 12.4% in OctoberInvestors are expecting lower Doximity revenue from advertising.
Nov 7, 2022 by James HalleyWhy Verve Therapeutics' Stock Dropped 26.33% on MondayA trial for the company's lead therapy was put on hold.
Nov 7, 2022 by James HalleyWhy Shares of CRISPR Therapeutics Dropped 19.9% in OctoberSeveral factors weighed on the gene-editing biotech stocks last month.
Nov 7, 2022 by James Halley2 Pet Medicine Stocks That Make Great Long-Term InvestmentsTwo of the biggest names in animal care continue to grow.
Nov 5, 2022 by James Halley2 Under-the-Radar Medtech Stocks to Buy NowDon't count out these discounted medical technology stocks.
Nov 5, 2022 by James HalleyIs Johnson & Johnson's Purchase of Abiomed Good for Investors?The $16.6 billion acquisition shakes up MedTech.
